Purpose To review the impact of collaborative studies on advances in the biology and
treatment of acute lymphoblastic leukemia (ALL) in children and adolescents. Methods A …

Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks
between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous …

Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk
subtype characterized by genomic alterations that activate cytokine receptor and kinase …

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as
BCR-ABL1–like ALL, is a high-risk subset with a gene expression profile that shares …

Down syndrome (also known as trisomy 21) is the model human phenotype for all genomic
gain dosage imbalances, including microduplications. The functional genomic exploration of …

Genomic profiling has identified a subtype of high-risk B-progenitor acute lymphoblastic
leukemia (B-ALL) with alteration of IKZF1, a gene expression profile similar to BCR-ABL1 …

Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL)
results in high cure rates in pediatric patients but is suboptimal in the treatment of adult …

Improved supportive care, more precise risk stratification, and personalized chemotherapy
based on the characteristics of leukemic cells and hosts (eg, pharmacokinetics and …

The cytokine TSLP has been shown to be a key factor in maintaining immune homeostasis
and regulating inflammatory responses at mucosal barriers. While the role of TSLP in type 2 …

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is
central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane …